Literature DB >> 31248535

Creation of a Flight Nurse Critical Care Ultrasound Program.

Michael Cover1, Chelsea Tafoya2, Benjamin Long2, James Cranford3, John Burkhardt4, Robert Huang4, Nik Theyyunni4, Benjamin Bassin4, Mark Lowell4, Ross Kessler4.   

Abstract

OBJECTIVE: Our objectives were 2-fold: to describe the creation of a flight nurse (FN) ultrasound (US) program and to evaluate whether critical care US performed by nonphysician providers in the prehospital setting can clarify patient assessment.
METHODS: Twenty FNs completed a didactic and hands-on US curriculum focusing on critical care modalities. FNs displayed competency by successful completion of an objective-structured clinical examination. Portable US devices were used during patient transports when deemed clinically indicated by the FN. If US was subsequently performed, the FN was asked if US use prompted a change in assessment. Associations were evaluated with chi-square and bivariate logistic regression analyses.
RESULTS: FNs reported US use during 102 (12.3%) patient transports, of which intensive care unit (ICU) to ICU (58.8%) constituted the majority of cases followed by emergency department (ED) to ED (28.4%), ED to ICU (4.9%), and scene to ED (2.9%). FNs agreed or strongly agreed that US use clarified the cause of patient symptoms in 67.4% of transports.
CONCLUSION: FNs were more likely to perform US when they expressed lower confidence in their initial patient assessment. FNs reported that US helped to clarify patient assessments.
Copyright © 2019 Air Medical Journal Associates. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31248535     DOI: 10.1016/j.amj.2019.03.010

Source DB:  PubMed          Journal:  Air Med J        ISSN: 1067-991X


  1 in total

1.  The Utilization of Handheld Ultrasound Devices in a Prehospital Setting.

Authors:  Kamonwon Ienghong; Lap Woon Cheung; Somsak Tiamkao; Vajarabhongsa Bhudhisawasdi; Korakot Apiratwarakul
Journal:  Prehosp Disaster Med       Date:  2022-04-18       Impact factor: 2.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.